Drug Users' Willingness to Encourage Social, Sexual, and Drug Network Members to Receive an HIV Vaccine: a Social Network Analysis

Overview

Journal AIDS Behav

Specialty Infectious Diseases

Date 2014 May 23

PMID 24849621

Citations 8

Authors

A M Young

R J DiClemente

D S Halgin

C E Sterk

J R Havens

Affiliations

Soon will be listed here.

Abstract

This study examined feasibility of peer-based promotion of HIV vaccination and dyadic correlates to vaccine encouragement in risk- and non-risk networks of drug users (n = 433) in the US. Data were collected on HIV vaccine attitudes, risk compensation intentions, likelihood of encouraging vaccination, and recent (past 6 months) risk (i.e. involving sex and/or injecting drugs) and non-risk (i.e. involving co-usage of noninjected drugs and/or social support) relationships. Willingness to encourage HIV vaccination was reported in 521 and 555 risk- and non-risk relationships, respectively. However, 37 % expressed hesitancy, typically due to fear of side effects or social concerns. Encouragement was often motivated by perceived HIV risk, though 9 % were motivated by risk compensation intentions. In non-risk partnerships, encouragement was associated with drug co-usage, and in risk relationships, with perceived vaccine acceptability and encouragement by the partner. Network-based HIV vaccine promotion may be a successful strategy, but risk compensation intentions should be explored.

Citing Articles

Promoting HPV Vaccination in People with HIV: Factors to Consider.

Huff K, Braun A, Salvaggio M, McGough P, Frank-Pearce S, Kendzor D Int J Environ Res Public Health. 2023; 20(7).

PMID: 37047959 PMC: 10094493. DOI: 10.3390/ijerph20075345.

Sociometric network analysis in illicit drugs research: A scoping review.

Zakimi N, Greer A, Bouchard M, Dhillon A, Ritter A PLoS One. 2023; 18(2):e0282340.

PMID: 36848370 PMC: 9970099. DOI: 10.1371/journal.pone.0282340.

Network-Based Research on Rural Opioid Use: an Overview of Methods and Lessons Learned.

Young A, Rudolph A, Havens J Curr HIV/AIDS Rep. 2018; 15(2):113-119.

PMID: 29457200 PMC: 5884725. DOI: 10.1007/s11904-018-0391-2.

Attitudes Toward the Ethics of Research Using Social Media: A Systematic Review.

Golder S, Ahmed S, Norman G, Booth A J Med Internet Res. 2017; 19(6):e195.

PMID: 28588006 PMC: 5478799. DOI: 10.2196/jmir.7082.

Quality of Care and Service Expansion for HIV Care and Treatment.

Moore C, Ciaraldi E Curr HIV/AIDS Rep. 2015; 12(2):223-30.

PMID: 25855339 DOI: 10.1007/s11904-015-0263-y.

References

Rudy E, Newman P, Duan N, Kelly E, Roberts K, Seiden D . HIV vaccine acceptability among women at risk: perceived barriers and facilitators to future HIV vaccine uptake. AIDS Educ Prev. 2005; 17(3):253-67. DOI: 10.1521/aeap.17.4.253.66529. View

Havens J, Lofwall M, Frost S, Oser C, Leukefeld C, Crosby R . Individual and network factors associated with prevalent hepatitis C infection among rural Appalachian injection drug users. Am J Public Health. 2012; 103(1):e44-52. PMC: 3518360. DOI: 10.2105/AJPH.2012.300874. View

Stover J, Bollinger L, Hecht R, Williams C, Roca E . The impact of an AIDS vaccine in developing countries: a new model and initial results. Health Aff (Millwood). 2007; 26(4):1147-58. DOI: 10.1377/hlthaff.26.4.1147. View

van Griensvan F, Keawkungwal J, Tappero J, Sangkum U, Pitisuttithum P, Vanichseni S . Lack of increased HIV risk behavior among injection drug users participating in the AIDSVAX B/E HIV vaccine trial in Bangkok, Thailand. AIDS. 2004; 18(2):295-301. DOI: 10.1097/00002030-200401230-00020. View

Newman P, Roungprakhon S, Tepjan S, Yim S, Walisser R . A social vaccine? Social and structural contexts of HIV vaccine acceptability among most-at-risk populations in Thailand. Glob Public Health. 2012; 7(9):1009-24. DOI: 10.1080/17441692.2012.692388. View

Young A, Havens J . Transition from first illicit drug use to first injection drug use among rural Appalachian drug users: a cross-sectional comparison and retrospective survival analysis. Addiction. 2011; 107(3):587-96. PMC: 3262084. DOI: 10.1111/j.1360-0443.2011.03635.x. View

Newman P, Lee S, Duan N, Rudy E, Nakazono T, Boscardin J . Preventive HIV vaccine acceptability and behavioral risk compensation among a random sample of high-risk adults in Los Angeles (LA VOICES). Health Serv Res. 2009; 44(6):2167-79. PMC: 2796320. DOI: 10.1111/j.1475-6773.2009.01039.x. View

Frew P, Archibald M, Martinez N, Del Rio C, Mulligan M . Promoting HIV Vaccine Research in African American Communities: Does the Theory of Reasoned Action Explain Potential Outcomes of Involvement?. Challenge (Atlanta Ga). 2010; 13(2):61-97. PMC: 2913490. View

Newman P, Woodford M, Logie C . HIV vaccine acceptability and culturally appropriate dissemination among sexually diverse Aboriginal peoples in Canada. Glob Public Health. 2011; 7(1):87-100. DOI: 10.1080/17441692.2010.549139. View

10.

Newman P, Roungprakhon S, Tepjan S, Yim S . Preventive HIV vaccine acceptability and behavioral risk compensation among high-risk men who have sex with men and transgenders in Thailand. Vaccine. 2009; 28(4):958-64. DOI: 10.1016/j.vaccine.2009.10.142. View

11.

Woodhouse D, Rothenberg R, Potterat J, Darrow W, Muth S, Klovdahl A . Mapping a social network of heterosexuals at high risk for HIV infection. AIDS. 1994; 8(9):1331-6. DOI: 10.1097/00002030-199409000-00018. View

12.

Newman P, Duan N, Rudy E, Roberts K, Swendeman D . Posttrial HIV vaccine adoption: concerns, motivators, and intentions among persons at risk for HIV. J Acquir Immune Defic Syndr. 2004; 37(3):1393-403. DOI: 10.1097/01.qai.0000127064.84325.ad. View

13.

Crosby R, Oser C, Leukefeld C, Havens J, Young A . Prevalence of HIV and risky sexual behaviors among rural drug users: does age matter?. Ann Epidemiol. 2012; 22(11):778-82. PMC: 3490025. DOI: 10.1016/j.annepidem.2012.07.006. View

14.

Frew P, Archibald M, Hixson B, Del Rio C . Socioecological influences on community involvement in HIV vaccine research. Vaccine. 2011; 29(36):6136-43. PMC: 3170874. DOI: 10.1016/j.vaccine.2011.06.082. View

15.

Kakinami L, Newman P, Lee S, Duan N . Differences in HIV vaccine acceptability between genders. AIDS Care. 2008; 20(5):542-6. PMC: 2836013. DOI: 10.1080/09540120701867180. View

16.

Valente T, Zogg J, Christensen S, Richardson J, Kovacs A, Operskalski E . Using social networks to recruit an HIV vaccine preparedness cohort. J Acquir Immune Defic Syndr. 2009; 52(4):514-23. PMC: 2783777. DOI: 10.1097/QAI.0b013e3181acff91. View

17.

Barrington C, Moreno L, Kerrigan D . Local understanding of an HIV vaccine and its relationship with HIV-related stigma in the Dominican Republic. AIDS Care. 2007; 19(7):871-7. DOI: 10.1080/09540120701203295. View

18.

Andersson K, Paltiel A, Owens D . The potential impact of an HIV vaccine with rapidly waning protection on the epidemic in Southern Africa: examining the RV144 trial results. Vaccine. 2011; 29(36):6107-12. PMC: 3164284. DOI: 10.1016/j.vaccine.2011.06.076. View

19.

Jenkins R, Thapinta D, Morgan P, Wongkamhaeng S, Sornsathapornkul P, Bussaratid V . Behavioral and social issues among volunteers in a preventive HIV vaccine trial in Thailand. J Acquir Immune Defic Syndr. 2005; 40(5):592-9. DOI: 10.1097/01.qai.0000171725.09812.a5. View

20.

Newman P, Logie C, James L, Charles T, Maxwell J, Salam K . "Speaking the dialect": understanding public discourse in the aftermath of an HIV vaccine trial shutdown. Am J Public Health. 2011; 101(9):1749-58. PMC: 3154228. DOI: 10.2105/AJPH.2011.300208. View